Archives for July, 2018

Upcoming Conferences: AAIC & NDD

July 22-26, Alliance representatives are attending the Alzheimer’s Association International Conference® (AAIC) in Chicago.   July 30-August 1, we’ll be in Boston for the Neuropsychiatric Drug Development Summit (NDD).   We look forward to hearing from knowledgeable speakers and meeting with industry associates to discuss our capabilities and extensive experience with Alzheimer’s and other mental…

Read More

David Walling, Ph.D. Quoted in Press Release Announcing FDA Approval of Alkermes’ ARISTADA INITIO™ for Schizophrenia

Alkermes plc today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO™ (aripiprazole lauroxil) for the initiation of ARISTADA® (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides…

Read More